PMID- 33839963
OWN - NLM
STAT- MEDLINE
DCOM- 20210622
LR  - 20210622
IS  - 1437-7772 (Electronic)
IS  - 1341-9625 (Linking)
VI  - 26
IP  - 7
DP  - 2021 Jul
TI  - Association of albumin-bilirubin score in patients with colorectal cancer 
      receiving later-line chemotherapy with regorafenib.
PG  - 1257-1263
LID - 10.1007/s10147-021-01910-2 [doi]
AB  - BACKGROUND: Regorafenib is recognized as a later-line standard treatment in 
      patients with metastatic colorectal cancer (mCRC). In this study, we examined the 
      association of the albumin-bilirubin (ALBI) score in patients with mCRC receiving 
      later-line chemotherapy with regorafenib. PATIENTS AND METHODS: We 
      retrospectively analyzed data from patients with mCRC treated with regorafenib in 
      a later line between January 2013 and December 2019. Patients were divided into a 
      Normal-ALBI group (ALBI grade 1) and a High-ALBI group (ALBI grades 2 and 3). 
      Primary endpoint was median overall survival (OS) and secondary endpoints were 
      median time to treatment failure (TTF) and incidence of adverse events (AEs). 
      RESULTS: Data from 60 patients were analyzed (Normal-ALBI group: 32 patients and 
      High-ALBI group: 28 patients). Median OS [10.23 vs. 3.70 months, hazard ratio 
      (HR): 1.79, 95% confidence interval (CI) 1.02-3.13, p = 0.041] and median TTF 
      (2.27 vs. 1.78 months, HR: 1.78, 95%CI 1.02-3.09, p = 0.042) were significantly 
      longer in the Normal-ALBI group than High-ALBI group. On Cox proportional hazard 
      analysis, ALBI score was significantly correlated with OS. The incidence of liver 
      dysfunction (grade >/= 2) was significantly higher in the High-ALBI than the 
      Normal-ALBI group (42.9% vs. 15.6%, p = 0.041), whereas other AEs were comparable 
      between the two groups. CONCLUSION: ALBI was strongly associated with the 
      prognosis of patients with mCRC treated with regorafenib and with the occurrence 
      of liver-related adverse events. These findings may imply that patients with a 
      high ALBI score should not be treated with regorafenib.
FAU - Watanabe, Daichi
AU  - Watanabe D
AD  - Department of Pharmacy, Gifu University Hospital, Yanagido 1-1, Gifu, 501-1194, 
      Japan.
FAU - Fujii, Hironori
AU  - Fujii H
AD  - Department of Pharmacy, Gifu University Hospital, Yanagido 1-1, Gifu, 501-1194, 
      Japan. h_fujii@gifu-u.ac.jp.
FAU - Yamada, Yunami
AU  - Yamada Y
AD  - Department of Pharmacy, Gifu University Hospital, Yanagido 1-1, Gifu, 501-1194, 
      Japan.
FAU - Matsuhashi, Nobuhisa
AU  - Matsuhashi N
AD  - Department of Surgical Oncology, Gifu University Graduate School of Medicine, 
      Gifu, Japan.
FAU - Makiyama, Akitaka
AU  - Makiyama A
AD  - Department of Surgical Oncology, Gifu University Graduate School of Medicine, 
      Gifu, Japan.
FAU - Iihara, Hirotoshi
AU  - Iihara H
AD  - Department of Pharmacy, Gifu University Hospital, Yanagido 1-1, Gifu, 501-1194, 
      Japan.
FAU - Takahashi, Takao
AU  - Takahashi T
AD  - Department of Surgical Oncology, Gifu University Graduate School of Medicine, 
      Gifu, Japan.
FAU - Kiyama, Shigeru
AU  - Kiyama S
AD  - Department of Surgical Oncology, Gifu University Graduate School of Medicine, 
      Gifu, Japan.
FAU - Kobayashi, Ryo
AU  - Kobayashi R
AD  - Department of Pharmacy, Gifu University Hospital, Yanagido 1-1, Gifu, 501-1194, 
      Japan.
FAU - Yoshida, Kazuhiro
AU  - Yoshida K
AD  - Department of Surgical Oncology, Gifu University Graduate School of Medicine, 
      Gifu, Japan.
FAU - Suzuki, Akio
AU  - Suzuki A
AD  - Department of Pharmacy, Gifu University Hospital, Yanagido 1-1, Gifu, 501-1194, 
      Japan.
LA  - eng
PT  - Journal Article
DEP - 20210411
PL  - Japan
TA  - Int J Clin Oncol
JT  - International journal of clinical oncology
JID - 9616295
RN  - 0 (Albumins)
RN  - 0 (Phenylurea Compounds)
RN  - 0 (Pyridines)
RN  - 24T2A1DOYB (regorafenib)
RN  - RFM9X3LJ49 (Bilirubin)
SB  - IM
MH  - Albumins
MH  - Bilirubin
MH  - *Colorectal Neoplasms/drug therapy
MH  - Humans
MH  - *Liver Neoplasms/drug therapy
MH  - Phenylurea Compounds
MH  - Prognosis
MH  - Pyridines
MH  - Retrospective Studies
OTO - NOTNLM
OT  - Albumin-bilirubin score
OT  - Metastatic colorectal cancer
OT  - Overall survival
OT  - Regorafenib
OT  - Tumor response
EDAT- 2021/04/12 06:00
MHDA- 2021/06/23 06:00
CRDT- 2021/04/11 20:55
PHST- 2020/12/14 00:00 [received]
PHST- 2021/03/24 00:00 [accepted]
PHST- 2021/04/12 06:00 [pubmed]
PHST- 2021/06/23 06:00 [medline]
PHST- 2021/04/11 20:55 [entrez]
AID - 10.1007/s10147-021-01910-2 [pii]
AID - 10.1007/s10147-021-01910-2 [doi]
PST - ppublish
SO  - Int J Clin Oncol. 2021 Jul;26(7):1257-1263. doi: 10.1007/s10147-021-01910-2. Epub 
      2021 Apr 11.